DelveInsight’s ‘Keratoconus (KC) - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Keratoconus (KC), historical and forecasted epidemiology as well as the Keratoconus (KC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Keratoconus (KC) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Keratoconus (KC) market size from 2017 to 2030. The report also covers current Keratoconus (KC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Keratoconus (KC) Overview
Keratoconus (KC) also known as the conical cornea, is an eye (ocular) disorder characterized by progressive thinning and changes in the shape of the cornea. The cornea is the thin, clear outer layer of the eye and is normally dome-shaped. Slowly progressive thinning of the cornea causes a cone-shaped bulge to develop towards the center of the cornea in the areas of greatest thinning. Affected individuals develop a blurry or distorted vision, sensitivity to light (photophobia), and additional vision problems. KC has different types based on the shape and location of the thinned cornea. These types include nipple, oval, keratoglobus, and D-shaped KC.
Generally, KC is first diagnosed in young people at puberty or in their late teens. The exact cause of KC is unknown. There are many theories based on research and its association with other conditions such as allergies and genetic causes; however, no one theory explains it all, and it may be caused by a combination of things.
In its earliest stages, KC is known to cause slight blurring and distortion of vision and increased sensitivity to glare and light; these symptoms usually appear in the late teens or early 20s. It may progress for 10–20 years and then slow in its progression. Each eye may be affected differently.
The specific underlying mechanism(s) responsible for KC are not fully understood. Most cases appear to occur randomly for unknown reasons (sporadically). However, a positive family history of KC has been established in some cases. Most researchers believe that multiple, complex factors are required for the development of KC, including both genetic and environmental factors.
KC should be suspected in any patient with significant irregular astigmatism, especially if unstable and increasing over time. In the early stages of the disease, there is altered metabolic activity that may lead to biomechanical instability and stretching of the corneal tissues. As the disease progresses, there is accompanying tissue loss. In addition, there is a loss of correlation between the anterior and posterior corneal curvature. Progressive corneal thinning and distortion causes a conical or cone-shaped protrusion, which may be visible at the slit lamp in advanced cases. In early disease, the condition may go undiagnosed unless assessments of the posterior and anterior corneal surfaces are undertaken using corneal tomography.
KC may be diagnosed based upon a complete patient and family history and thorough eye examination. Such an examination may include evaluation of the external appearance of the eyes, visual acuity, eye movements, and visual fields; the use of a special, illuminated microscope that allows physicians to view the eye through high magnification (slit-lamp examination); and/or additional tests or procedures.
Various diagnostic techniques and procedures used for KC include:
The initial treatment for keratoconus often consists of hard contact lenses. A variety of keratorefractive procedures have also been attempted, broadly divided into subtractive and additive techniques. Subtractive techniques include photorefractive keratectomy or laser in situ keratomileusis, although generally, the results of these techniques have been poor. Implantation of intrastromal corneal ring segments is an additive technique in which the implants are intended to reinforce the cornea, prevent further deterioration, and potentially obviate the need for penetrating keratoplasty. Penetrating keratoplasty (i.e., corneal grafting) is the last line of treatment.
About 20% of patients with keratoconus will require corneal transplantation. All of these treatments attempt to improve refractive errors but are not disease-modifying.
However, keratoconus management has significantly changed over the last two decades. The advent of new interventions such as cornea cross-linking, intrastromal corneal ring segments and combined treatments provide corneal clinicians a variety of treatment options for the visual rehabilitation of keratoconus patients.
Corneal collagen cross-linking (CXL) has the potential to slow the progression of the disease. During CXL, in order to achieve a strengthening effect of corneal tissue and arrest keratoconus progression, the use of riboflavin (vitamin B2) is combined with ultraviolet A (UV-A) irradiation. Riboflavin plays the role of a photosensitizer in the photopolymerization process and when combined with UV-A irradiation increases the formation of intrafibrillar and interfibrillar carbonyl-based collagen covalent bonds through a molecular process that has still not been completely elucidated.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Keratoconus (KC), Severity-specific Distribution of Keratoconus (KC) and Age-specific Distribution of Keratoconus (KC) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
This section provides glimpse of the Keratoconus (KC) epidemiology in the 7MM.
The epidemiology segment also provides the Keratoconus (KC) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The drug chapter segment of the Keratoconus (KC) report encloses the detailed analysis of Keratoconus (KC) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Keratoconus (KC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Photrexa Viscous and Photrexa: Glaukos/ Avedro
Photrexa Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa (riboflavin 5’-phosphate ophthalmic solution) are photoenhancers indicated for use with the KXL System in corneal collagen cross-linking. The KXL System is an electronic medical device that delivers ultraviolet light (365 nm wavelength) in a circular pattern onto the cornea after riboflavin phosphates ophthalmic solution (Photrexa Viscous and/or Photrexa) has been applied. They are the first and only FDA approved therapeutic treatment of progressive keratoconus (KC) and corneal ectasia following refractive surgery.
Product details in the report…
Avedro’s scientifically-developed family of CE marked riboflavin formulations—VibeX Xtra, VibeX Rapid, ParaCel, MedioCROSS TE, MedioCROSS M, MedioCROSS D, and MedioCROSS H—ensure rapid diffusion in individual, sterile syringes for all cross-linking needs. These multiple CE marked riboflavin formulations have set the standard to produce the highest quality riboflavin since the introduction of corneal cross-linking. Avedro’s riboflavin formulations have been used in hundreds of thousands of treatments around the world. The company distributes its products in 62 countries through 33 ophthalmic distributors with 115 sales and service representatives. The products are not for sale in the US.
Product details in the report…
Ricrolin is a hypotonic ophthalmic solution containing Ribofl¬avin (0.1%), specifically formulated to allow quick passage of Riboflavin into the corneal stroma, either through the healthy epithelium or after de-epithelization or even by using a low-intensity electrical field applied topically (iontophoresis). This solution, used on the eye, combined with an emitter of ultraviolet (UV-A) rays, is indicated for the conservative parasurgical treatment of the keratoconus and of corneal ectasia diseases. When administering Ricrolin using iontophoresis, the transepithelial riboflavin penetration, aided by the application of a low-intensity electric field, facilitates the corneal cross-linking operation by shortening absorption time, thereby reducing patient discomfort.
Product details in the report…
Lightmed developed Collagex riboflavin (vitamin B2) family, which is an essential component of any corneal cross‐linking procedure. It is considered as the purest and most advanced riboflavin in the market and is redefined as the ultra hi-quality riboflavin solution. It is supplied in a convenient glass syringe applicator and individually packed in sterile pouches available for use in conjunction with LightMed LightLink CXL corneal cross linking system, or as generic formula. The product is exclusively produced and packaged by a “Class II” GMP accredited Manufacturing Pharmacy under fully aseptic conditions. This Collagex family consists of several products that are distinguished based on their compositions. These products include Collagex—Isotonic, Collagex—Hypotonic, Collagex—Trans-Epithelial (TE), Collagex—Rapid, and Collagex—Plus.
Product details in the report…
Peschke Riboflavin solutions initialize the formation of new collagen cross-links and protect the eye against the UV-A light applied during the corneal cross-linking procedure. These solutions are available in the various formulations, namely, Peschke TE, Peschke M, Peschke D, Peschke H and Peschke L. These Peschke Riboflavin solution formulations are used in conjunction with the PXL Platinum 330 system. The PXL Platinum 330 treatment is intended to induce corneal collagen cross-linking to improve the biomechanical properties of the cornea by strengthening the corneal tissue in the anterior stroma. This cross-linking procedure is useful for treating Corneal Ectasia, Keratoconus, Iatrogenic Ectasia, Pellucid Marginal Degeneration (PMD), and Infectious keratitis.
Product details in the report…
IVMED-80: iVeena Delivery Systems
IVMED-80 is the first twice-daily, eye-drop, non-surgical, non-UV light treatment for medical crosslinking of the cornea. The drug, with its copper-based formulation, is reportedly the first eye drop designed to treat keratoconus (KC) without the need for adjunctive laser treatment or surgical intervention. IVMED-80’s mechanism of action centers on enhancing the activity of lysyl oxidase (LOX) – the enzyme responsible for corneal collagen crosslinking, and also known to be associated with KC and copper, which is a co-factor of LOX, is the active ingredient of the drug. In February 2019, the company announced the commencement of a 36 patient phase I/IIa pilot clinical study for the treatment of mild and moderate KC (IVMED-80) and presented an abstract of the trial in the 2020 ARVO Annual Meeting.
Product details in the report…
According to the Cornea Research Foundation of America, Keratoconus (KCN) is a disease characterized by thinning and protrusion of the cornea, resulting in an irregular, conical shape. Irregular astigmatism occurs as the KC progresses, and results in blurred vision, which can be impossible to correct with spectacles. Usually, keratoconus occurs in both eyes, and involves the central cornea with the apex of the cone just below the visual axis. Approximately 50–200 of every 100,000 people are afflicted with KC. In the US, a study found a prevalence of 54.5 per 100,000 people.
The current treatment option includes the use of cornea cross-linking, intrastromal corneal ring segments, and other combined treatments, which provide the corneal clinicians a variety of treatment options for the visual rehabilitation of KC patients. In the mildest form of keratoconus, eyeglasses or soft contact lenses are preferred. But as the disease progresses and the cornea thins and becomes increasingly more irregular in shape, glasses and regular soft contact lens designs no longer provide adequate vision correction. The treatment of progressive KC includes corneal collagen cross-linking or CXL, custom soft contact lenses, gas permeable contact lenses, “Piggy backing”, contact lenses, Hybrid contact lenses, Scleral and semi-scleral lenses, Prosthetic lenses, Topography-guided conductive keratoplasty (CK), and corneal transplant.
In addition to these therapies, the US FDA has approved Avedro’s Photrexa and Photrexa Viscous photoenhancers indicated for use with the KXL System in corneal collagen cross-linking for the treatment of patients with progressive KC and post-LASIK ectasia. Although the EMA does not approve this therapy; however, it was used in Europe way before its FDA approval in April 2016 as a CE marked product.
Cross-linking is approved by the FDA for halting the progression of KC. Once the condition progresses, FDA has approved Intacs or a cornea transplant as more advanced treatment options. Crosslinking utilizes riboflavin drops (Vitamin B2) and ultraviolet light, which interact with the corneal tissue to create “cross-links” between corneal proteins. This strengthens the cornea, which is weak in keratoconus, to decrease KC progression.
In addition to standard riboflavin formulations comparable to the US FDA-approved ophthalmic solutions, a variety of modified riboflavin formulations are in use in regions outside the United States and are regulated under the CE Mark in the European Union.
These formulations have not been evaluated by the US FDA and are not approved for sale in the United States. These formulations include the Avedro’s family of CE marked riboflavin (VibeX Xtra, VibeX Rapid, ParaCel, MedioCROSS TE, MedioCROSS M, MedioCROSS D, and MedioCROSS H), Lightmed’s Collagex riboflavin (vitamin B2) family of products which includes- Collagex—Isotonic, Collagex—Hypotonic, Collagex—Trans-Epithelial (TE), Collagex—Rapid, and Collagex—Plus and Sooft Italia’s Ricrolin.
Other than these CE marked products that are being marketed in Europe, Peschke Riboflavin is also available in the European market. These solutions are also available in different formulations, namely Peschke TE, Peschke M, Peschke D, Peschke H, and Peschke L..
These Peschke Riboflavin solution formulations are used in conjunction with the PXL Platinum 330 system.
The current pipeline holds a major unmet need for the novel and potential emerging therapy. The emerging emerging-market holds IVMED-80, which is under development by iVeena Delivery Systems to treat KC without the need for adjunctive laser treatment or surgical intervention. The drug is in phase I/II clinical-developmental trial.
This section includes a glimpse of the Keratoconus (KC) 7MM market.
This section provides the total Keratoconus (KC) market size and market size by therapies in the United States.
The total Keratoconus (KC) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Keratoconus (KC) market size and market size by therapies in Japan are provided.
This section focusses on the rate of uptake of the potential drugs recently launched in the Keratoconus (KC) market or expected to get launched in the market during the study period 2017–2030. The analysis covers Keratoconus (KC) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Keratoconus (KC) emerging therapies.
We perform competitive and market Intelligence analysis of the Keratoconus (KC) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
1. Key Insights
2. Executive Summary of Keratoconus
3. Competitive Intelligence Analysis for Keratoconus
4. Keratoconus: Market Overview at a Glance
4.1. Keratoconus Total Market Share (%) Distribution in 2017
4.2. Keratoconus Total Market Share (%) Distribution in 2030
5. Keratoconus: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Keratoconus Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Keratoconus Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Keratoconus Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Keratoconus Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Keratoconus Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Keratoconus Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Keratoconus Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Keratoconus Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Keratoconus Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Keratoconus Treatment and Management
8.2. Keratoconus Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Keratoconus Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Keratoconus: Seven Major Market Analysis
13.1. Key Findings
13.2. Keratoconus Market Size in 7MM
13.3. Keratoconus Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Keratoconus Total Market Size in the United States
15.1.2. Keratoconus Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Keratoconus Total Market Size in Germany
15.3.2. Keratoconus Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Keratoconus Total Market Size in France
15.4.2. Keratoconus Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Keratoconus Total Market Size in Italy
15.5.2. Keratoconus Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Keratoconus Total Market Size in Spain
15.6.2. Keratoconus Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Keratoconus Total Market Size in the United Kingdom
15.7.2. Keratoconus Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Keratoconus Total Market Size in Japan
15.8.3. Keratoconus Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Keratoconus
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
*The table of contents is not exhaustive; the final content may vary.
List of Table
Table 1 Summary of KC, Market, Epidemiology and Key Events (2017–2030)
Table 2 Amsler-Krumeich Classification for grading KC
Table 3 ABCD Grading System for classifying KC
Table 4 Total Diagnosed Prevalent Population of Keratoconus in the 7MM (2017–2030)
Table 5 Total Diagnosed Prevalent Population of Keratoconus in the United States (2017–2030)
Table 6 Severity-specific Distribution of Keratoconus in the United States (2017–2030)
Table 7 Age-specific Distribution of Keratoconus in the United States (2017–2030)
Table 8 Total Diagnosed Prevalent Population of Keratoconus in Germany (2017–2030)
Table 9 Severity-specific Distribution of Keratoconus in Germany (2017–2030)
Table 10 Age-specific Distribution of Keratoconus in Germany (2017–2030)
Table 11 Total Diagnosed Prevalent Population of Keratoconus in France (2017–2030)
Table 12 Severity-specific Distribution of Keratoconus in France (2017–2030)
Table 13 Age-specific Distribution of Keratoconus in France (2017–2030)
Table 14 Total Diagnosed Prevalent Population of Keratoconus in Italy (2017–2030)
Table 15 Severity-specific Distribution of Keratoconus in Italy (2017–2030)
Table 16 Age-specific Distribution of Keratoconus in Italy (2017–2030)
Table 17 Total Diagnosed Prevalent Population of Keratoconus in Spain (2017–2030)
Table 18 Severity-specific Distribution of Keratoconus in Spain (2017–2030)
Table 19 Age-specific Distribution of Keratoconus in Spain (2017–2030)
Table 20 Total Diagnosed Prevalent Population of Keratoconus in the United Kingdom (2017–2030)
Table 21 Severity-specific Distribution of Keratoconus in the United Kingdom (2017–2030)
Table 22 Age-specific Distribution of Keratoconus in the United Kingdom (2017–2030)
Table 23 Total Diagnosed Prevalent Population of Keratoconus in Japan (2017–2030)
Table 24 Severity-specific Distribution of Keratoconus in Japan (2017–2030)
Table 25 Age-specific Distribution of Keratoconus in Japan (2017–2030)
Table 26 Paracel; Clinical Trial Description,2020
Table 27 Seven Major Market Size of Keratoconus (KC) in USD Million (2017–2030)
Table 28 Total Market Size of Keratoconus (KC) in the United States, in USD Million (2017–2030)
Table 29 Market size of Keratoconus (KC) by therapies in the United States, in USD Million (2017–2030)
Table 30 Total Market Size of Keratoconus (KC) in Germany, in USD Million (2017–2030)
Table 31 Market size of Keratoconus (KC) by therapies in Germany, in USD Million (2017–2030)
Table 32 Total Market Size of Keratoconus (KC) in France, in USD Million (2017–2030)
Table 33 Market size of Keratoconus (KC) by therapies in France, in USD Million (2017–2030)
Table 34 Total Market Size of Keratoconus (KC) in Italy, in USD Million (2017–2030)
Table 35 Market size of Keratoconus (KC) by therapies in Italy, in USD Million (2017–2030)
Table 36 Total Market Size of Keratoconus (KC) in Spain, in USD Million (2017–2030)
Table 37 Market size of Keratoconus (KC) by therapies in Spain, in USD Million (2017–2030)
Table 38 Total Market Size of Keratoconus (KC) in the United Kingdom, in USD Million (2017–2030)
Table 39 Market size of Keratoconus (KC) by therapies in the United Kingdom, in USD Million (2017–2030)
Table 40 Total Market Size of Keratoconus (KC) in Japan, in USD Million (2017–2030)
Table 41 Market size of Keratoconus (KC) by therapies in Japan, in USD Million (2017–2030)
List of Figure
Figure 1 Total Diagnosed Prevalent Population of Keratoconus in the 7MM (2017–2030)
Figure 2 Total Diagnosed Prevalent Population of Keratoconus in the United States (2017–2030)
Figure 3 Severity-specific Distribution of Keratoconus in the United States (2017–2030)
Figure 4 Age-specific Distribution of Keratoconus in the United States (2017–2030)
Figure 5 Total Diagnosed Prevalent Population of Keratoconus in Germany (2017–2030)
Figure 6 Severity-specific Distribution of Keratoconus in Germany (2017–2030)
Figure 7 Age-specific Distribution of Keratoconus in Germany (2017–2030)
Figure 8 Total Diagnosed Prevalent Population of Keratoconus in France (2017–2030)
Figure 9 Severity-specific Distribution of Keratoconus in France (2017–2030)
Figure 10 Age-specific Distribution of Keratoconus in France (2017–2030)
Figure 11 Total Diagnosed Prevalent Population of Keratoconus in Italy (2017–2030)
Figure 12 Severity-specific Distribution of Keratoconus in Italy (2017–2030)
Figure 13 Age-specific Distribution of Keratoconus in Italy (2017–2030)
Figure 14 Total Diagnosed Prevalent Population of Keratoconus in Spain (2017–2030)
Figure 15 Severity-specific Distribution of Keratoconus in Spain (2017–2030)
Figure 16 Age-specific Distribution of Keratoconus in Spain (2017–2030)
Figure 17 Total Diagnosed Prevalent Population of Keratoconus in the United Kingdom (2017–2030)
Figure 18 Severity-specific Distribution of Keratoconus in the United Kingdom (2017–2030)
Figure 19 Age-specific Distribution of Keratoconus in the United Kingdom (2017–2030)
Figure 20 Total Diagnosed Prevalent Population of Keratoconus in Japan (2017–2030)
Figure 21 Severity-specific Distribution of Keratoconus in Japan (2017–2030)
Figure 22 Age-specific Distribution of Keratoconus in Japan (2017–2030)
Figure 23 Keratoconus Treatment Algorithm
Figure 24 Unmet Needs of KC
Figure 25 Seven Major Market Size of Keratoconus (KC) in USD Million (2017–2030)
Figure 26 Total Market Size of Keratoconus (KC) in the United States, USD Millions (2017–2030)
Figure 27 Market size of Keratoconus (KC) by therapies in the United States, in USD Million (2017–2030)
Figure 28 Total Market Size of Keratoconus (KC) in Germany, USD Millions (2017–2030)
Figure 29 Market size of Keratoconus (KC) by therapies in Germany, in USD Million (2017–2030)
Figure 30 Total Market Size of Keratoconus (KC) in France, USD Millions (2017–2030)
Figure 31 Market size of Keratoconus (KC) by therapies in France, in USD Million (2017–2030)
Figure 32 Total Market Size of Keratoconus (KC) in Italy, USD Millions (2017–2030)
Figure 33 Market size of Keratoconus (KC) by therapies in Italy, in USD Million (2017–2030)
Figure 34 Total Market Size of Keratoconus (KC) in Spain, USD Millions (2017–2030)
Figure 35 Market size of Keratoconus (KC) by therapies in Spain, in USD Million (2017–2030)
Figure 36 Total Market Size of Keratoconus (KC) in the United Kingdom, USD Millions (2017–2030)
Figure 37 Market size of Keratoconus (KC) by therapies in the United Kingdom, in USD Million (2017–2030)
Figure 38 Total Market Size of Keratoconus (KC) in Japan, USD Millions (2017–2030)
Figure 39 Market size of Keratoconus (KC) by therapies in Japan, in USD Million (2017–2030)
Figure 40 Market Drivers
Figure 41 Market Barriers
Figure 42 SWOT Analysis
Glaukos/Avedro
Avedro/ Glaukos Corporation
Sooft Italia
Lightmed_OptiMed
Peschke Meditrade GmbH
iVeena Delivery Systems
And Many Others
